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Abstract
Infantile-onset multisystem neurologic, endocrine, and pancreatic disease (IMNEPD) has been recently linked to
biallelic mutation of the peptidyl-tRNA hydrolase 2 gene PTRH2. Two index patients with IMNEPD in the original
report had multiple neurological symptoms such as postnatal microcephaly, intellectual disability, developmental
delay, sensorineural deafness, cerebellar atrophy, ataxia, and peripheral neuropathy. In addition, distal muscle
weakness and abnormalities of thyroid, pancreas, and liver were found. Here, we report five further IMNEPD patients
with a different homozygous PTRH2 mutation, broaden the phenotypic spectrum of the disease and differentiate
common symptoms and interindividual variability in IMNEPD associated with a unique mutation. We thereby hope
to better define IMNEPD and promote recognition and diagnosis of this novel disease entity.
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Introduction
The infantile-onset multisystem neurologic, endocrine,
and pancreatic disease (IMNEPD; MIM#616263) was re-
cently reported by us as a novel disease entity in two indi-
viduals from a consanguineous family of Yazidian-Turkish
descent [1]. We further demonstrated the association of a
homozygous nonsense mutation in the PTRH2 gene
(MIM*608625) to IMNEPD through functional and mo-
lecular data in human and mouse [1]. The two index pa-
tients in the original report presented with postnatal
microcephaly, moderate intellectual disability, abnormal
rhythmic rapid activity on EEG, sensorineural deafness,
and delayed speech development. They suffered from dis-
tal muscle weakness and delayed motor milestones, and
later developed progressive ataxia and progressive cerebel-
lar atrophy. Peripheral demyelinating sensorimotor neur-
opathy and endocrine abnormalities with affection of the
pancreas, thyroid, and liver were furthermore present [1].
Our single-family report was rapidly further supported by
a second case without detailed analysis of the disease
phenotype [2]. Here, we report five further IMNEPD pa-
tients from two consanguineous families with a PTRH2
missense mutation and discuss their phenotype, thereby il-
lustrating both core and variable features of IMNEPD.
Material and methods
Informed consent was obtained from the parents of the
patients for the molecular genetic analysis, the publica-
tion of clinical data, photos, magnetic resonance images
(MRI) and studies on fibroblasts. DNA extraction from
blood samples and Sanger sequencing was performed
using standard protocols. Samples from patients and
controls were used in this study with approval from the
local ethics committees of the Charité (approval no.
EA1/212/08). Quantitative real-time PCR (qPCR) and
Western blot were performed with established methods
reported previously [1]. Primer sequences are provided
in the supplementary data (Additional file 1: Table S3).
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Results
We report five IMNEPD patients from two consanguin-
eous families of Tunisian and Saudi Arabian descent, all
with the homozygous missense mutation c.254A > C in
exon 2 of the PTRH2 gene (NM_016077.4; Fig. 1). This
mutation causes an amino acid exchange of glutamate to
proline (p.Q85P, NP_057161, Fig. 1a) and putatively af-
fects structure, folding, and stability of PTRH2 by alter-
ing hydrogen bridge bonds within the protein [2]. In line
with this, PTRH2 protein levels were strongly reduced in
Fig. 1 Genotype and phenotype of index patients with IMNEPD. a Scheme of PTRH2 mRNA and protein indicating the site of mutations in exon 2, the
only coding exon of PTRH2. The mutation c.254A > C was previously reported [2]. b Electopherograms depicting the PTRH2 nonsense mutation of the
original IMNEPD family (left) and the missense mutation of the further identified IMNEPD families (right). c Pedigrees of consanguineous families with
IMNEPD (left: family 1 previously reported in Hu et al. 2014 [1], middle: family 2, right: family 3). d Mild facial dysmorphism of IMNEPD patients with
phenotypic variability. Some patients show mild midface hypoplasia, a thin upper lip vermilion, and bilateral ptosis. e Cranial MRI of index patients (top:
sagittal, below: coronal plane). Both patients with a PTRH2 missense mutation (family I, II.2 and II.4) show marked cerebellar atrophy while only one
patient with a missense mutation (patient II.1, family 3) was diagnosed with cerebellar atrophy (white arrows)
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fibroblasts from patient II.1, family 2, while PTRH2 mRNA
levels were unchanged (Additional file 2: Figure S1). The
mutation segregates with the disease phenotype and is het-
erozygous in the healthy parents of the patients. Patient
II.10, family 3, was previously reported, without detailed
clinical information, in a large genetic screening study on
consanguineous families with developmental delay [2].
Neurologic core features of (almost) all patients were in-
tellectual disability, motor delay, severe speech delay,
ataxia, and sensorineural hearing loss (Table 1, Additional
file 3: Table S1). Furthermore, exocrine pancreatic insuffi-
ciency with reduced pancreas elastase levels was detected
in almost all patients. It was partly associated with con-
secutive deficiency of lipophilic vitamins and failure to
thrive in the first years of life (Table 1). Insufficiency of
the endocrine pancreas function in IMNEPD had already
been suggested based on the marginal HbA1c elevation in
an index patient of the original IMNEPD family [1] and is
now supported by a clinically manifest diabetes mellitus of
patient II.4, family 2 (Additional file 4: Table S2). In this
patient abdominal sonography at age 9 had shown a
hyperechogenic pancreas indicating lipomatosis, and pan-
creatic atrophy was now diagnosed by magnetic resonance
imaging at the age of 17 years (Fig. 2). Hepatomegaly had
already been detected in the index patients of the first
IMNEPD family [1], but it had remained unclear whether
hepatomegaly resulted from fibrosis or steatosis. A liver
biopsy performed in patient II.4, family 2, for hepatomeg-
aly and slightly increased transaminase values now re-
vealed hepatic micro- and macrosteatosis (Fig. 1). Slightly
increased transaminase values and lactate dehydrogenase
activities in further patients could indicate a mild liver
(and/or muscle disease) (Additional file 4: Table S2). Des-
pite the identification of the same PTRH2 mutation in all
five patients, phenotypic variability could be observed. For
instance, facial palsy, distal muscle weakness, truncal
hypotonia, peripheral demyelinating neuropathy, and
cerebellar atrophy were only occasionally present (Table 1).
Further minor features were skeletal anomalies, especially
anomalies of the fingers, and mild facial abnormalities
such as exotropia, ptosis, and thin upper lip vermilion.
Discussion
Ptrh2 is an evolutionarily well conserved mitochondrial
protein, which prevents the accumulation of dissociated
peptidyl-tRNAs and thus an inhibition of protein synthe-
sis [3]. As part of an integrin signaling complex, Ptrh2
regulates the fine balance between cell survival and
apoptosis; it also has a role in cell size control [1, 4–7].
We recently highlighted the role of PTRH2 for human
development by linking a homozygous PTRH2 gene
nonsense mutation (c.269_270delCT, p.A90fs) to the dis-
ease infantile multisystem neurologic, endocrine, and
pancreatic disease (IMNEPD) [1]. Since the original
description, we have identified five further patients of
three consanguineous families of Tunisian and Saudi
Arabian descent with an IMNEPD phenotype and a
homozygous missense mutation of PTRH2 (c.254A > C,
p.Q85P; Fig. 1). The mutation causes a strong downreg-
ulation and a predicted dysfunction of the PTRH2 pro-
tein (Additional file 2: Figure S1) [2]. Comparison of the
phenotype of the original and the newly identified fam-
ilies illustrates both core features and phenotypic vari-
ability of this novel disease entity (Table 1). The core
phenotype, mutual to almost all affected patients, com-
prises intellectual disability, motor and severe speech
delay, ataxia, sensorineural hearing loss, and pancreatic
insufficiency (Table 1, Additional file 3: Table S1). Pro-
gressive cerebellar atrophy and ataxia imposed as key
features of IMNEPD in the index family with a homozy-
gous nonsense mutation of PTRH2. This was further
underlined given the phenotype of mutant Ptrh2 mice
with microcephaly and severe cerebellar atrophy [1].
However, in the light of PTRH2 missense mutations –
presumably with higher residual PTRH2 levels - progres-
sive cerebellar atrophy was present in only one patient.
The lack of cerebellar atrophy in some patients with a
homozygous PTRH2 missense mutation and the lack of
microcephaly in all patients with a homozygous PTRH2
missense mutation may be attributed to interindividual
variability and/or correlate with the quantity or residual
function of PTRH2. Ataxia was present in almost all
IMNEPD patients, also in those without cerebellar hypo-
trophy/atrophy, suggesting that ataxia may not be attrib-
uted exclusively to progressive cerebellar atrophy, but
could also result from demyelinating peripheral neur-
opathy detected in several patients (Table 1). Apart from
variations in the neurologic phenotype, both patients with
the nonsense mutation had hypothyroidism, while thyrox-
ine values in all patients with the missense mutation were
normal. However, two patients with a missense mutation
presented with elevated thyroxine stimulating hormones
(TSH), likely indicating latent thyroid insufficiency. Hep-
atomegaly and/or abnormal liver parenchyma morphology
on ultrasound were present in both patients with a non-
sense mutation and one patient with a missense mutation
of PTRH2. We had speculated before that hepatomegaly
and abnormal liver echogenicity were due to fibrosis or
steatosis, and we can now demonstrate diffuse and exten-
sive micro- and macrosteatosis in a liver biopsy specimen
of patient II.4, family 2. Pancreatic insufficiency is a fea-
ture present in most IMNEPD patients: exocrine insuffi-
ciency was identified in both patients with a nonsense
mutation and four patients with a missense mutation;
signs of endocrine insufficiency were found in both
patients with the nonsense mutation (borderline HbA1c
elevation) and in one patient with the missense mutation
(insulin-dependent diabetes mellitus). In the latter
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Table 1 Phenotype of index patients with IMNEPD
Ethnic background Yazidian-Turkish Yazidian-Turkish Tunesian Saudi-Arabian Saudi-Arabian Saudi-Arabian Saudi-Arabian
Mutation c.269_270delCT c.269_270delCT c.254A > C c.254A > C c.254A > C c.254A > C c.254A > C
Family 01 01 02 03 03 03 03
Pedigree ID (gender) II.1 (♀) II.4 (♂) II.4 (♂) II.1 (♀) II.2 (♂) II.10 (♂) II.13 (♂))
Age at last assessment (years) 14 3/12 6 8/12 15 7 6/12 5 6/12 13 3
Category Feature HPO
Growth
Height Postnatal growth retardation
(years at onset)
0001530 + (11.4) + (4) - - - - -
Weight Failure to thrive (years at onset) 0001508 + (11.4) + (4) - + (1.8) + (2.2) - -
Head and Neck
Head Postnatal microcephaly (OFC < P3;
years at onset)
0005484 + (2.5) + (0.3) - - - - -
Brachycephaly 0000248 + + + - - - -
Face Abnormality of the midface 0000309 + + (+) - - - -
Facial palsy 0010628 + + + + - - -
Ears Sensorineural hearing impairment 0000399 + + + + + + +
Eyes Hypertelorism 0000316 + + - - - - -
Exotropia 0000577 + + - + - - +
Mouth Thin upper lip vermilion 0000219 + + - + + - -
Abdomen
Liver Hepatomegaly 0002240 - + + - - - -
Abnormal liver parenchyma
morphology (on ultrasound)
0030146 + + + - - - -
Pancreas Exocrine pancreatic insufficiency 0001738 + + + NA NA + +
Hyperechogenic pancreas 0006276 + - + - - - -
Pancreatic atrophy (on MRI) 0100800 - - + - - - -
Genitourinary
External genitalia Shawl scrotum 0000049 - + NA NA - - -
Skeletal
Pelvis Congenital hip dislocation 0001374 + + - - - - -
Hands Proximal placement of thumb 0009623 + + + + + - -
Long fingers 0100807 + + + + + - -















Table 1 Phenotype of index patients with IMNEPD (Continued)
Feet Abnormality of the hallux 0001844 + - - - - - -
Talipes equinovalgus, incipient 0001772 + - + - - - -
Achilles tendon contracture 0001771 + - - + + + -
Neurologic
Central nervous system Neonatal hypotonia 0001319 + + + - - - -
Motor delay 0001270 + + + + + + +
Distal muscle weakness 0002460 + + + + + - -
Intellectual disability, moderate (IQ 39–70) 0002342 + (48) + (39) NA + (65–70) + (55–65) + (57) +
Dysmetria 0001310 + NA + + - -
Ataxia 0001251 + + + + + + -
Cerebellar hypoplasia, progressive 0100307 + + - - + - -
EEG abnormality: alpha-beta-waves even
in sleep
0002353 + + - NA NA NA NA
Peripheral nervous
system
Demyelinating sensorimotor neuropathy 0003431,0003448 + + + NA NA NA NA
Muscle Skeletal muscle fibrosis (on ultrasound) - + + NA NA NA NA NA
Endocrine features
Hypothyroidism 0000821 + + - - - - -
Diabetes mellitus 0000819 (+) (+) + - - - -
Prenatal manifestations
Movement Decreased fetal movement 0001558 + - - - - - -















pancreatic steatosis and atrophy were diagnosed (Fig. 2).
Substitution of lipophilic vitamins in the index patients of
the original IMNEPD family markedly improved growth
of the patients [1]. The main differential diagnosis of
IMNEPD is the syndrome short stature, microcephaly,
and endocrine dysfunction (SSMED, MIM#616541), which
similarly comprises microcephaly, ataxia, polyneuropathy,
endocrine dysfunction, and sporadically cerebellar atro-
phy. Short stature and microcephaly are already present at
birth in patients with SSMED, while they develop
postnataly in IMNEPD. Also, patients with SSMED
may additionally have ophthalmological and cardiac
abnormalities, a thin corpus callosum, and wide cere-
bral ventricles. Further differential diagnoses include
Pearson marrow-pancreas syndrome (MIM#557000),
Cockayne syndrome (MIM#216400, MIM#133540),
Johanson-Blizzard syndrome (MIM#243800) and meta-
bolic acidosis, encephalopathy, lactate acidosis, and stroke
(MELAS, MIM#540000), all depicting a variable combin-
ation of sensorineural deafness, ataxia, endocrine abnor-
malities, pancreas, and/or liver affection. These syndromes
can be distinguished from IMNEPD by the additional
presence of facial dysmorphism or urogenital defects
(Johanson-Blizzard syndrome), ophthalmological, cardiac,
or splenic involvement (Pearson marrow-pancreas syn-
drome, Cockayne syndrome, MELAS), photosensitivity/
dry skin (Cockayne syndrome), blood count or bone mar-
row abnormalities (Pearson marrow-pancreas syndrome,
Johanson-Blizzard syndrome), metabolic acidosis (Pearson
marrow-pancreas syndrome, MELAS), or encephalopathy
(MELAS). With this second report of IMNEPD we are still
at the beginning of understanding the genotype-phenotype-
correlation and interindividual phenotype variability of the
disease. Since IMNEPD affects many organ systems, raising
awareness for this disease entity among (pediatric) en-
docrinologists, gastroenterologists, diabetologists, and
neurologists will likely propagate recognition and diag-
nosis of IMNEPD and, ultimately, improve treatment of
affected patients.
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IMNEPD: infantile-onset multisystem neurologic, endocrine, and pancreatic
disease; PTRH2: peptidyl-tRNA hydrolase 2 gene; MRI: magnetic resonance
image.
Fig. 2 Liver and pancreas affection of IMNEPD patient a Paraffin embedded sections of the liver biopsy of index patient II.4, family 2 at x20
magnification (left) and x100 magnification (right) after haematoxilin safran staining show diffuse micro- and macrosteatosis (black arrows). b (i)
Pancreas sonography of index patient II.4, family 2 at age 9 showing hyperechogenicity (white arrows). (ii) Pancreatic magnetic resonance imaging
of patient II.4, family 2 at age 17 showing pancreatic atrophy (white arrows)
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